This Week’s CGT News: Off-the-Shelf CAR T Tackles Kidney Cancer - Summary - MDSpire

This Week’s CGT News: Off-the-Shelf CAR T Tackles Kidney Cancer

Allogeneic CAR T produces durable responses in advanced kidney cancer, the FDA clears a CD22-directed in vivo therapy, and Repligen agrees to acquire BioLife Solutions for $1.5 billion

  • July 27, 2026

  • 5 min

Share

Original Source(s)

This Week’s CGT News: Off-the-Shelf CAR T Tackles Kidney Cancer

  • July 27, 2026

Related Content

ASCO26: Alicia Morgans, MD, MPH, ARACOG

Dr. Alicia Morgans of Dana-Farber Cancer Institute reported at #ASCO26 that ARACOG found darolutamide was associated with less decline in cognitive testing than enzalutamide, which may help guide treatment choice.

  • July 1, 2026

  • 1 min
The Power List 2026 is Live

We celebrate 60 inspiring individuals helping turn pharma’s boldest ideas into reality

  • July 21, 2026

  • 1 min
cfDNA’s Big Moment Has Arrived

Experts explore the promise, pitfalls, and future of cfDNA testing in modern laboratory medicine